Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 287 articles:
HTML format

Single Articles

    March 2023
  1. LIU E, Zhang F, Xu T, Ye L, et al
    Relationship between tumor microbiota transcriptional activity and gene expression in breast cancer.
    BMC Cancer. 2023;23:252.
    PubMed     Abstract available

  2. ZHANG C, Qi L, Cai J, Wu H, et al
    Clinicomics-guided distant metastasis prediction in breast cancer via artificial intelligence.
    BMC Cancer. 2023;23:239.
    PubMed     Abstract available

  3. MA R, Wei W, Ye H, Dang C, et al
    A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy.
    BMC Cancer. 2023;23:245.
    PubMed     Abstract available

  4. TAKADA K, Kashiwagi S, Iimori N, Kouhashi R, et al
    Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer.
    BMC Cancer. 2023;23:224.
    PubMed     Abstract available

  5. SANDAMALI JAN, Hewawasam RP, Fernando MACSS, Jayatilaka KAPW, et al
    Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka.
    BMC Cancer. 2023;23:210.
    PubMed     Abstract available

  6. MA Y, Lv M, Yuan P, Chen X, et al
    Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2023;23:208.
    PubMed     Abstract available

  7. RYU J, Lee EY, Min J, Yeon S, et al
    Effect of a 1-year tailored exercise program according to cancer trajectories in patients with breast cancer: study protocol for a randomized controlled trial.
    BMC Cancer. 2023;23:200.
    PubMed     Abstract available

    February 2023
  8. KARACIN C, Oksuzoglu B, Demirci A, Keskinkilic M, et al
    Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
    BMC Cancer. 2023;23:192.

  9. LUO J, Kibriya MG, Chen H, Kim K, et al
    A metabolome-wide case-control study of african american breast cancer patients.
    BMC Cancer. 2023;23:183.
    PubMed     Abstract available

  10. SHI Q, Yu J, Liu D, Ren F, et al
    Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
    BMC Cancer. 2023;23:173.
    PubMed     Abstract available

  11. RASHA F, Boligala GP, Yang MV, Martinez-Marin D, et al
    Dishevelled 2 regulates cancer cell proliferation and T cell mediated immunity in HER2-positive breast cancer.
    BMC Cancer. 2023;23:172.
    PubMed     Abstract available

  12. RASHED A, Fitzpatrick OM, Easty DJ, Coyne Z, et al
    An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer.
    BMC Cancer. 2023;23:171.
    PubMed     Abstract available

  13. AL-KEILANI MS, Bdeir R, Elstaty RI, Alqudah MA, et al
    Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
    BMC Cancer. 2023;23:158.
    PubMed     Abstract available

  14. VOLKEL V, Steinger B, Koller M, Klinkhammer-Schalke M, et al
    Colorectal cancer survivors' long-term recollections of their illness and therapy up to seven years after enrolment into a randomised controlled clinical trial.
    BMC Cancer. 2023;23:149.
    PubMed     Abstract available

  15. KARACIN C, Oksuzoglu B, Demirci A, Keskinkilic M, et al
    Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
    BMC Cancer. 2023;23:136.
    PubMed     Abstract available

  16. GHEYBI E, Asoodeh A, Amani J
    Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice.
    BMC Cancer. 2023;23:134.
    PubMed     Abstract available

  17. CHEN X, Zhang J, Lei X, Yang L, et al
    CD1C is associated with breast cancer prognosis and immune infiltrates.
    BMC Cancer. 2023;23:129.
    PubMed     Abstract available

  18. AFAYA A, Laari TT, Seidu AA, Afaya RA, et al
    Factors associated with the uptake of clinical breast examination among women of reproductive age in Lesotho: analysis of a national survey.
    BMC Cancer. 2023;23:114.
    PubMed     Abstract available

    January 2023
  19. PIVOT X, Manikhas AG, Shamrai V, Dzagnidze G, et al
    Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.
    BMC Cancer. 2023;23:112.
    PubMed     Abstract available

  20. YANG J, Zhao B, Ling X, Li D, et al
    Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
    BMC Cancer. 2023;23:103.
    PubMed     Abstract available

  21. SHAO Z, Yu J, Cheng Y, Ma W, et al
    MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer.
    BMC Cancer. 2023;23:97.
    PubMed     Abstract available

  22. JIA Z, Dai M, Shang Y, Li Y, et al
    Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy.
    BMC Cancer. 2023;23:93.
    PubMed     Abstract available

  23. ZHOU S, Lv H, Li A, Li M, et al
    A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio >/= 2.0 and an average HER2 copy number < 4.0 per cell in China.
    BMC Cancer. 2023;23:84.
    PubMed     Abstract available

  24. LIEDE A, Sebby W, Miriyala AKR, Potluri R, et al
    Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
    BMC Cancer. 2023;23:78.
    PubMed     Abstract available

  25. TAN Z, Zou Y, Zhu M, Luo Z, et al
    Correction: Carnitine palmitoyl transferase 1 A is a novel diagnostic and predictive biomarker for breast cancer.
    BMC Cancer. 2023;23:40.

  26. ZHANG C, Liang Z, Liu W, Zeng X, et al
    Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
    BMC Cancer. 2023;23:37.
    PubMed     Abstract available

  27. VERBEEK JGE, de Jong VMT, Wijnja HM, Jager A, et al
    High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.
    BMC Cancer. 2023;23:26.
    PubMed     Abstract available

  28. DENG H, Wang L, Wang N, Zhang K, et al
    Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data.
    BMC Cancer. 2023;23:29.
    PubMed     Abstract available

  29. HUANG S, Yang Q, Zheng X, Chow KM, et al
    Predictors of surgery choices in women with early-stage breast cancer in China: a retrospective study.
    BMC Cancer. 2023;23:23.
    PubMed     Abstract available

  30. LIU S, Du S, Gao S, Teng Y, et al
    A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients.
    BMC Cancer. 2023;23:15.
    PubMed     Abstract available

  31. NAFISSI N, Meshkati Yazd SM, Shahriarirad R, Zangeneh S, et al
    Postoperative cosmetic outcome of intraoperative radiotherapy in comparison to whole breast radiotherapy in early stage breast cancer; a retrospective cohort study.
    BMC Cancer. 2023;23:9.
    PubMed     Abstract available

    December 2022
  32. ZIMBALIST AS, Caan BJ, Chen WY, Mittendorf EA, et al
    Metabolic abnormalities and survival among patients with non-metastatic breast cancer.
    BMC Cancer. 2022;22:1361.
    PubMed     Abstract available

  33. YANG H, Xu L, Guan S, Hao X, et al
    Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
    BMC Cancer. 2022;22:1357.
    PubMed     Abstract available

  34. QI WX, Cao L, Zheng S, Xu C, et al
    IMNI PRECISION trial protocol: a phase II, open-label, non-inferior randomized controlled trial of tailoring omission of internal mammary node irradiation for early-stage breast cancer.
    BMC Cancer. 2022;22:1356.
    PubMed     Abstract available

  35. BEATTY L, Kemp E, Butow P, Girgis A, et al
    Finding My Way-Advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial.
    BMC Cancer. 2022;22:1353.
    PubMed     Abstract available

  36. ALLAHYARI A, Ehsanpour A, Najafi B, Ansarinejad N, et al
    Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
    BMC Cancer. 2022;22:1348.

  37. MAHTANI R, Niyazov A, Arondekar B, Lewis K, et al
    Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from th
    BMC Cancer. 2022;22:1343.
    PubMed     Abstract available

  38. YAO H, Li N, Yuan H
    Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
    BMC Cancer. 2022;22:1337.
    PubMed     Abstract available

  39. KLAESTAD E, Opdahl S, Raj SX, Bofin AM, et al
    Long term trends of breast cancer incidence according to proliferation status.
    BMC Cancer. 2022;22:1340.
    PubMed     Abstract available

  40. ZHANG GY, Zhang R, Bai P, Li SM, et al
    Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    BMC Cancer. 2022;22:1331.
    PubMed     Abstract available

  41. GENG SK, Fu SM, Zhang HW, Fu YP, et al
    Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer.
    BMC Cancer. 2022;22:1328.
    PubMed     Abstract available

  42. BRUAND M, Salleron J, Guihard S, Crety CM, et al
    Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort.
    BMC Cancer. 2022;22:1318.
    PubMed     Abstract available

  43. SIRAIT LMF, Hamajima N, Suzuki Y, Wahyuningsih ES, et al
    Factors associated with positive cancer screening for the uterine cervix and breast in Jakarta Province, Indonesia: a cross-sectional study.
    BMC Cancer. 2022;22:1309.
    PubMed     Abstract available

  44. TERASHIMA T, Konishi H, Sato Y, Igarashi M, et al
    Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: a nationwide study.
    BMC Cancer. 2022;22:1303.
    PubMed     Abstract available

  45. BODARD S, Lassalle L, Larousserie F, Guinebert S, et al
    Performance of Sonoelastography for predicting malignancy in soft tissue.
    BMC Cancer. 2022;22:1305.
    PubMed     Abstract available

  46. VOUTILAINEN S, Heikkila P, Bartkova J, Nevanlinna H, et al
    Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of gammaH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
    BMC Cancer. 2022;22:1298.
    PubMed     Abstract available

  47. ZHU P, Liu G, Wang X, Lu J, et al
    Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis.
    BMC Cancer. 2022;22:1283.
    PubMed     Abstract available

  48. LI M, Zheng Y, Li X, Shen X, et al
    ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer.
    BMC Cancer. 2022;22:1280.
    PubMed     Abstract available

  49. YOUSEFI H, Bahramy A, Zafari N, Delavar MR, et al
    Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer.
    BMC Cancer. 2022;22:1282.
    PubMed     Abstract available

  50. GORMAN LS, Ruane H, Woof VG, Southworth J, et al
    The co-development of personalised 10-year breast cancer risk communications: a 'think-aloud' study.
    BMC Cancer. 2022;22:1264.
    PubMed     Abstract available

  51. XU D, Xu N, Sun L, Yang Z, et al
    TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway.
    BMC Cancer. 2022;22:1267.
    PubMed     Abstract available

  52. PAIK HJ, Kim SJ, Kim KS, Kim Y, et al
    Characteristics and chronologically changing patterns of late-onset breast cancer in Korean women of age >/= 70 years: A hospital based-registry study.
    BMC Cancer. 2022;22:1261.
    PubMed     Abstract available

  53. DE LA CRUZ-MERINO L, Gion M, Cruz J, Alonso-Romero JL, et al
    Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.
    BMC Cancer. 2022;22:1258.
    PubMed     Abstract available

  54. DRAGVOLL I, Bofin AM, Soiland H, Taraldsen G, et al
    Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer.
    BMC Cancer. 2022;22:1247.
    PubMed     Abstract available

  55. JIANG C, Xiu Y, Yu X, Qiao K, et al
    Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.
    BMC Cancer. 2022;22:1249.
    PubMed     Abstract available

  56. LIANG X, Chen X, Yang Z, Liao Y, et al
    Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer.
    BMC Cancer. 2022;22:1250.
    PubMed     Abstract available

    November 2022
  57. MENG X, Li W, Meng Z, Li Y, et al
    EIF4A3-induced circBRWD3 promotes tumorigenesis of breast cancer through miR-142-3p_miR-142-5p/RAC1/PAK1 signaling.
    BMC Cancer. 2022;22:1225.
    PubMed     Abstract available

  58. URAS C, Cabioglu N, Tokat F, Er O, et al
    Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up.
    BMC Cancer. 2022;22:1217.
    PubMed     Abstract available

  59. FREITAS-JUNIOR R, de Oliveira VM, Frasson AL, Cavalcante FP, et al
    Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology.
    BMC Cancer. 2022;22:1201.
    PubMed     Abstract available

  60. SAXTON JM, Pickering K, Wane S, Humphreys H, et al
    Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer.
    BMC Cancer. 2022;22:1202.
    PubMed     Abstract available

  61. JM S, K P, S W, H C, et al
    The experiences and perceptions of female breast cancer patients regarding weight management during and after treatment for oestrogen-receptor positive disease: a qualitative study.
    BMC Cancer. 2022;22:1189.
    PubMed     Abstract available

  62. MEYER D, Pastor-Villaescusa B, Michel S, Hauner H, et al
    Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials.
    BMC Cancer. 2022;22:1187.
    PubMed     Abstract available

  63. KE L, Li S, Cui H
    The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:1185.
    PubMed     Abstract available

  64. LEE TH, Chang JH, Jang BS, Kim JS, et al
    Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy.
    BMC Cancer. 2022;22:1179.
    PubMed     Abstract available

  65. SHANG C, Chen Q, Zu F, Ren W, et al
    Integrated analysis identified prognostic microRNAs in breast cancer.
    BMC Cancer. 2022;22:1170.
    PubMed     Abstract available

  66. XIONG J, Zuo W, Wu Y, Wang X, et al
    Ultrasonography and clinicopathological features of breast cancer in predicting axillary lymph node metastases.
    BMC Cancer. 2022;22:1155.
    PubMed     Abstract available

  67. DITSATHAM C, Sripan P, Chaiwun B, Klunklin P, et al
    Breast Cancer Subtypes in Northern Thailand and Barriers to satisfactory survival outcomes.
    BMC Cancer. 2022;22:1147.
    PubMed     Abstract available

  68. SHARMNI VISHNU K, Win TT, Aye SN, Basavaraj AK, et al
    Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
    BMC Cancer. 2022;22:1139.
    PubMed     Abstract available

  69. XU T, Zhang SM, Wu HM, Wen XM, et al
    Prognostic significance of prognostic nutritional index and systemic immune-inflammation index in patients after curative breast cancer resection: a retrospective cohort study.
    BMC Cancer. 2022;22:1128.
    PubMed     Abstract available

  70. LI Y, Chen L, Lv J, Chen X, et al
    Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
    BMC Cancer. 2022;22:1125.
    PubMed     Abstract available

  71. ROGINSKI M, Sifaki-Pistolla D, Stomby A, Velivasaki G, et al
    Paradoxes of breast cancer incidence and mortality in two corners of Europe.
    BMC Cancer. 2022;22:1123.
    PubMed     Abstract available

  72. DE ALMEIDA MARQUES BERNABE R, de Souza Vieira M, Felicio de Souza V, Gomes Fontana L, et al
    Muscle strength is associated with fracture risk obtained by fracture risk assessment tool (FRAX) in women with breast cancer.
    BMC Cancer. 2022;22:1115.
    PubMed     Abstract available

    October 2022
  73. DEUTSCHMANN C, Bartsch R, Singer CF, Gschwantler-Kaulich D, et al
    Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria.
    BMC Cancer. 2022;22:1099.
    PubMed     Abstract available

  74. YAN D, Ju X, Luo B, Guan F, et al
    Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer.
    BMC Cancer. 2022;22:1082.
    PubMed     Abstract available

  75. CHERIFI F, Da Silva A, Johnson A, Blanc-Fournier C, et al
    HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
    BMC Cancer. 2022;22:1081.
    PubMed     Abstract available

  76. NABI-MEYBODI M, Sahebnasagh A, Hakimi Z, Shabani M, et al
    Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial.
    BMC Cancer. 2022;22:1079.
    PubMed     Abstract available

  77. HAYNES BM, Cunningham K, Shekhar MPV
    RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    BMC Cancer. 2022;22:1073.
    PubMed     Abstract available

  78. LIU L, Zhai W, Wang F, Yu L, et al
    Using machine learning to identify gene interaction networks associated with breast cancer.
    BMC Cancer. 2022;22:1070.
    PubMed     Abstract available

  79. KORONKIEWICZ M, Kazimierczuk Z, Orzeszko A
    Antitumor activity of the protein kinase inhibitor 1-(beta-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.
    BMC Cancer. 2022;22:1069.
    PubMed     Abstract available

  80. ISMAIL AL-KHALIL W, Al-Salhi L, Rijjal S, Aljamali M, et al
    The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
    BMC Cancer. 2022;22:1067.
    PubMed     Abstract available

  81. DI BENEDETTO C, Oh J, Choudhery Z, Shi W, et al
    NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer.
    BMC Cancer. 2022;22:1056.
    PubMed     Abstract available

  82. HAWKINS R, McWilliams L, Ulph F, Evans DG, et al
    Healthcare professionals' views following implementation of risk stratification into a national breast cancer screening programme.
    BMC Cancer. 2022;22:1058.
    PubMed     Abstract available

  83. ZHANG J, Dong D, Wei Q, Ren L, et al
    CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma.
    BMC Cancer. 2022;22:1052.
    PubMed     Abstract available

  84. WONG CHONG E, Joncas FH, Seidah NG, Calon F, et al
    Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
    BMC Cancer. 2022;22:1049.
    PubMed     Abstract available

  85. LEICHSENRING J, Vladimirova V, Solbach C, Karn T, et al
    EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
    BMC Cancer. 2022;22:1040.
    PubMed     Abstract available

  86. ZHANG L, She R, Zhu J, Lu J, et al
    Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer.
    BMC Cancer. 2022;22:1030.
    PubMed     Abstract available

    September 2022
  87. MCNAMEE N, de la Fuente LR, Santos-Martinez MJ, O'Driscoll L, et al
    Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation.
    BMC Cancer. 2022;22:1023.
    PubMed     Abstract available

  88. PIEK MW, de Boer JP, van Duijnhoven F, van der Wal JE, et al
    The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.
    BMC Cancer. 2022;22:1018.
    PubMed     Abstract available

  89. JEON Y, Jo U, Hong J, Gong G, et al
    Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
    BMC Cancer. 2022;22:1014.
    PubMed     Abstract available

  90. FONSECA MM, Alhassan T, Nisha Y, Koszycki D, et al
    Correction: Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
    BMC Cancer. 2022;22:1009.

  91. LINDMAN H, Wiklund F, Andersen KK
    Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
    BMC Cancer. 2022;22:1006.
    PubMed     Abstract available

  92. GONG M, Liu X, Zhao X, Wang H, et al
    A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation.
    BMC Cancer. 2022;22:1005.
    PubMed     Abstract available

  93. ARTHUR EK, Menon U, Reese JB, Browning K, et al
    Profiles of women's adjustment after cancer based on sexual and psychosocial wellbeing: results of a cluster analysis.
    BMC Cancer. 2022;22:1003.
    PubMed     Abstract available

  94. JIANG Y, Wang B, Li JK, Li SY, et al
    Collagen fiber features and COL1A1: are they associated with elastic parameters in breast lesions, and can COL1A1 predict axillary lymph node metastasis?
    BMC Cancer. 2022;22:1004.
    PubMed     Abstract available

  95. FILLBRUNN M, Signorovitch J, Andre F, Wang I, et al
    PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
    BMC Cancer. 2022;22:1002.
    PubMed     Abstract available

  96. HAJJ A, Khoury R, Hachem R, Awad A, et al
    Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the "CAGE-Cog" study.
    BMC Cancer. 2022;22:996.
    PubMed     Abstract available

  97. MCCLELLAN B, Gries P, Harlow B, Tiziani S, et al
    An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer.
    BMC Cancer. 2022;22:976.
    PubMed     Abstract available

  98. AL SAAD S, Al Shenawi H, Almarabheh A, Al Shenawi N, et al
    Is laterality in breast Cancer still worth studying? Local experience in Bahrain.
    BMC Cancer. 2022;22:968.
    PubMed     Abstract available

  99. ALLAHYARI A, Ehsanpour A, Ansarinejad N, Mehrzad V, et al
    Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
    BMC Cancer. 2022;22:960.
    PubMed     Abstract available

  100. PEPE FF, Cazzaniga ME, Baroni S, Riva F, et al
    Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 stu
    BMC Cancer. 2022;22:956.
    PubMed     Abstract available

  101. WANG Y, Lu R, Chen P, Cui R, et al
    Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers.
    BMC Cancer. 2022;22:951.
    PubMed     Abstract available

  102. JIANG Y, Mason M, Cho Y, Chittiprolu A, et al
    Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
    BMC Cancer. 2022;22:950.
    PubMed     Abstract available

    August 2022
  103. MAHMOOD D, Ahmad A, Sharif F, Arslan SA, et al
    Clinical application of low-level laser therapy (Photo-biomodulation therapy) in the management of breast cancer-related lymphedema: a systematic review.
    BMC Cancer. 2022;22:937.
    PubMed     Abstract available

  104. WANG Q, Li B, Liu Z, Shang H, et al
    Prediction model of axillary lymph node status using automated breast ultrasound (ABUS) and ki-67 status in early-stage breast cancer.
    BMC Cancer. 2022;22:929.
    PubMed     Abstract available

  105. XU H, Zhang H, Guo W, Zhong X, et al
    Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
    BMC Cancer. 2022;22:923.
    PubMed     Abstract available

  106. XU H, Qi Z, Zhao Q, Xue J, et al
    Lentinan enhances the antitumor effects of Delta-like 1 via neutrophils.
    BMC Cancer. 2022;22:918.
    PubMed     Abstract available

  107. GETU MA, Chen C, Wang P, Kantelhardt EJ, et al
    Quality of life and its influencing factors among breast cancer patients at Tikur Anbessa specialised hospital, Addis Ababa, Ethiopia.
    BMC Cancer. 2022;22:897.
    PubMed     Abstract available

  108. NSAFUL J, Dedey F, Nartey E, Labi J, et al
    The impact of a breast cancer educational intervention in Ghanaian high schools.
    BMC Cancer. 2022;22:893.
    PubMed     Abstract available

  109. ZHANG K, Chen L, Zheng H, Zeng Y, et al
    Cytokines secreted from adipose tissues mediate tumor proliferation and metastasis in triple negative breast cancer.
    BMC Cancer. 2022;22:886.
    PubMed     Abstract available

  110. FONTVIEILLE E, His M, Biessy C, Navionis AS, et al
    Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study.
    BMC Cancer. 2022;22:877.
    PubMed     Abstract available

  111. ALNOUMAS L, van den Driest L, Apczynski Z, Lannigan A, et al
    Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets.
    BMC Cancer. 2022;22:874.
    PubMed     Abstract available

  112. XU A, Chu X, Zhang S, Zheng J, et al
    Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma.
    BMC Cancer. 2022;22:872.
    PubMed     Abstract available

  113. SHEN K, Yao L, Zhu J, Gu X, et al
    Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
    BMC Cancer. 2022;22:863.
    PubMed     Abstract available

  114. LI L, Li F, Hu X, Wu Z, et al
    LAP3 contributes to IFN-gamma-induced arginine depletion and malignant transformation of bovine mammary epithelial cells.
    BMC Cancer. 2022;22:864.
    PubMed     Abstract available

  115. CUSTODIO IDD, Nunes FSM, Lima MTM, de Carvalho KP, et al
    Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy.
    BMC Cancer. 2022;22:860.
    PubMed     Abstract available

  116. LIU PH, Wei JC, Wang YH, Yeh MH, et al
    Female breast cancer incidence predisposing risk factors identification using nationwide big data: a matched nested case-control study in Taiwan.
    BMC Cancer. 2022;22:849.
    PubMed     Abstract available

  117. KWON YJ, Seo EB, Jeong AJ, Lee SH, et al
    The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2022;22:852.
    PubMed     Abstract available

  118. ZHANG Y, Wu H, Yu Z, Li L, et al
    Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    BMC Cancer. 2022;22:842.
    PubMed     Abstract available

  119. CHO B, Perez M, Jeffe DB, Kreuter MW, et al
    Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.
    BMC Cancer. 2022;22:837.
    PubMed     Abstract available

    July 2022
  120. LIU N, Yang DW, Wu YX, Xue WQ, et al
    Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: an up-to-date overview and comparison with those in Japan and South Korea.
    BMC Cancer. 2022;22:826.
    PubMed     Abstract available

  121. RO V, Jones T, Silverman T, McGuinness JE, et al
    Patient, primary care provider, and stakeholder perspectives on mammography screening frequency: lessons learned from a qualitative study.
    BMC Cancer. 2022;22:819.
    PubMed     Abstract available

  122. BRAHIM SM, Zein EE, Bonnet C, Hamed CT, et al
    Screening of BRCA1/2 variants in Mauritanian breast cancer patients.
    BMC Cancer. 2022;22:802.
    PubMed     Abstract available

  123. BHAKKAN-MAMBIR B, Deloumeaux J, Luce D
    Geographical variations of cancer incidence in Guadeloupe, French West Indies.
    BMC Cancer. 2022;22:783.
    PubMed     Abstract available

  124. DOS SANTOS RLB, Pepe VLE, Osorio-de-Castro CGS
    Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019.
    BMC Cancer. 2022;22:769.
    PubMed     Abstract available

  125. FONSECA MM, Alhassan T, Nisha Y, Koszycki D, et al
    Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
    BMC Cancer. 2022;22:774.
    PubMed     Abstract available

  126. TOAMA W, Wiederin J, Shanley R, Jewett P, et al
    Impact of pectoralis muscle loss on cardiac outcome and survival in Cancer patients who received anthracycline based chemotherapy: retrospective study.
    BMC Cancer. 2022;22:763.
    PubMed     Abstract available

  127. JIA L, Li G, Ma N, Zhang A, et al
    Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction.
    BMC Cancer. 2022;22:760.
    PubMed     Abstract available

    June 2022
  128. KHAN MA, Zheng M, Fu J, Tania M, et al
    Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro.
    BMC Cancer. 2022;22:707.
    PubMed     Abstract available

  129. PATULEIA SIS, Moelans CB, Koopman J, van Steenhoven JEC, et al
    Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?
    BMC Cancer. 2022;22:705.
    PubMed     Abstract available

  130. BORDE J, Laitman Y, Blumcke B, Niederacher D, et al
    Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    BMC Cancer. 2022;22:706.
    PubMed     Abstract available

  131. REIS J, Boavida J, Tran HT, Lyngra M, et al
    Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.
    BMC Cancer. 2022;22:702.
    PubMed     Abstract available

  132. HU K, Wang C, Luo C, Zheng H, et al
    Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts.
    BMC Cancer. 2022;22:680.
    PubMed     Abstract available

  133. WOLF J, Kurz S, Rothe T, Serpa M, et al
    Incidental irradiation of the regional lymph nodes during deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a dosimetric analysis.
    BMC Cancer. 2022;22:682.
    PubMed     Abstract available

  134. DUZENLI C, Chan EK, Bergman AM, Grahame S, et al
    A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: a study protocol for a multicentre phase III randomized controlled trial.
    BMC Cancer. 2022;22:673.
    PubMed     Abstract available

  135. DARBEHESHTI F, Kadkhoda S, Keshavarz-Fathi M, Razi S, et al
    Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    BMC Cancer. 2022;22:668.
    PubMed     Abstract available

  136. SEHOVIC E, Urru S, Chiorino G, Doebler P, et al
    Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection.
    BMC Cancer. 2022;22:634.
    PubMed     Abstract available

  137. YELLAPU NK, Ly T, Sardiu ME, Pei D, et al
    Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
    BMC Cancer. 2022;22:627.
    PubMed     Abstract available

  138. OMARINI C, Piacentini F, Sperduti I, Cerma K, et al
    T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.
    BMC Cancer. 2022;22:623.
    PubMed     Abstract available

  139. LI XF, Fu WF, Zhang J, Song CG, et al
    An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
    BMC Cancer. 2022;22:619.
    PubMed     Abstract available

  140. WANG Y, Song W, Zhou S, Chang S, et al
    The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
    BMC Cancer. 2022;22:618.
    PubMed     Abstract available

  141. LI X, An C, Zhang W
    Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy.
    BMC Cancer. 2022;22:614.
    PubMed     Abstract available

    May 2022
  142. AMORNSUPAK K, Thongchot S, Thinyakul C, Box C, et al
    HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2022;22:578.
    PubMed     Abstract available

  143. TSENG CH
    Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
    BMC Cancer. 2022;22:559.
    PubMed     Abstract available

  144. BENTLEY JR, Yu X, Karmarkar AM, Downer B, et al
    Feasibility and thematic analysis of narrative visualization materials with physical activity monitoring among breast cancer survivors.
    BMC Cancer. 2022;22:553.
    PubMed     Abstract available

  145. REN X, Song Y, Zhang Y, Wu H, et al
    Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    BMC Cancer. 2022;22:548.
    PubMed     Abstract available

  146. KOHLS M, Freisling H, Charvat H, Soerjomataram I, et al
    Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study.
    BMC Cancer. 2022;22:546.
    PubMed     Abstract available

  147. SAYAN M, Eren MF, Kilic SS, Kotek A, et al
    Utilization of radiation therapy and predictors of noncompliance among Syrian refugees in Turkey.
    BMC Cancer. 2022;22:532.
    PubMed     Abstract available

  148. ZENG X, Jiang S, Ruan S, Zhu L, et al
    Cardiovascular risk factors and breast cancer incidence in a large middle-aged cohort study.
    BMC Cancer. 2022;22:534.
    PubMed     Abstract available

  149. ZHOU J, Sun X, Zhang X, Yang H, et al
    miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer.
    BMC Cancer. 2022;22:533.
    PubMed     Abstract available

  150. NGUYEN VAN LONG F, Lardy-Cleaud A, Carene D, Rossoni C, et al
    Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.
    BMC Cancer. 2022;22:526.
    PubMed     Abstract available

  151. ESER K, Onder AH, Sezer E, Cil T, et al
    Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
    BMC Cancer. 2022;22:516.
    PubMed     Abstract available

  152. BROWN J, Scardo S, Method M, Schlauch D, et al
    A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
    BMC Cancer. 2022;22:502.
    PubMed     Abstract available

  153. ROUX A, Cholerton R, Sicsic J, Moumjid N, et al
    Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.
    BMC Cancer. 2022;22:507.
    PubMed     Abstract available

  154. MITAL S, Nguyen HV
    Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
    BMC Cancer. 2022;22:501.
    PubMed     Abstract available

  155. MCLAUGHLIN PMJ, Klar M, Zwimpfer TA, Dutilh G, et al
    Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
    BMC Cancer. 2022;22:508.
    PubMed     Abstract available

  156. DELRIEU L, Hamy AS, Coussy F, Kassara A, et al
    Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.
    BMC Cancer. 2022;22:493.
    PubMed     Abstract available

    April 2022
  157. LI J, Li H, Guan L, Lu Y, et al
    The value of preoperative sentinel lymph node contrast-enhanced ultrasound for breast cancer: a large, multicenter trial.
    BMC Cancer. 2022;22:455.
    PubMed     Abstract available

  158. LEE HJ, Choi CH
    Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
    BMC Cancer. 2022;22:446.
    PubMed     Abstract available

  159. CHEN H, Luo H, Wang J, Li J, et al
    Identification of a pyroptosis-related prognostic signature in breast cancer.
    BMC Cancer. 2022;22:429.
    PubMed     Abstract available

  160. WINTRAECKEN VM, Vulik S, de Wild S, Dirksen C, et al
    A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer.
    BMC Cancer. 2022;22:426.
    PubMed     Abstract available

  161. HE Y, Han SB, Liu Y, Zhang JJ, et al
    Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer.
    BMC Cancer. 2022;22:411.
    PubMed     Abstract available

  162. LUNARDI M, Al-Habbaa A, Abdelshafy M, Davey MG, et al
    Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review.
    BMC Cancer. 2022;22:396.
    PubMed     Abstract available

  163. GONCALVES R, Mota BS, Sobreira-Lima B, Ricci MD, et al
    The oncological safety of autologous fat grafting: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:391.
    PubMed     Abstract available

  164. XIE Y, Gou Q, Zhang Y, Xie K, et al
    Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China.
    BMC Cancer. 2022;22:385.
    PubMed     Abstract available

  165. HOU C, Xu B, Hao Y, Yang D, et al
    Development and validation of polygenic risk scores for prediction of breast cancer and breast cancer subtypes in Chinese women.
    BMC Cancer. 2022;22:374.
    PubMed     Abstract available

  166. ZERELLA MA, Zaffaroni M, Ronci G, Dicuonzo S, et al
    Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study - a phase I/II clinical trial protocol.
    BMC Cancer. 2022;22:358.
    PubMed     Abstract available

  167. REYNOLDS LM, Cavadino A, Chin S, Little Z, et al
    The benefits and acceptability of virtual reality interventions for women with metastatic breast cancer in their homes; a pilot randomised trial.
    BMC Cancer. 2022;22:360.
    PubMed     Abstract available

    March 2022
  168. ZHU GL, Xu C, Yang KB, Tang SQ, et al
    Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization.
    BMC Cancer. 2022;22:353.
    PubMed     Abstract available

  169. SHEWELL LK, Day CJ, Kutasovic JR, Abrahams JL, et al
    N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.
    BMC Cancer. 2022;22:334.
    PubMed     Abstract available

  170. AMITANI M, Oba T, Kiyosawa N, Morikawa H, et al
    Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
    BMC Cancer. 2022;22:327.
    PubMed     Abstract available

  171. MANOUCHEHRI E, Taghipour A, Ebadi A, Homaei Shandiz F, et al
    Understanding breast cancer risk factors: is there any mismatch between laywomen perceptions and expert opinions.
    BMC Cancer. 2022;22:309.
    PubMed     Abstract available

  172. MARTEI YM, Dauda B, Vanderpuye V
    Correction: Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
    BMC Cancer. 2022;22:306.

  173. DEN DEKKER BM, Christenhusz A, van Dalen T, Jongen LM, et al
    A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial.
    BMC Cancer. 2022;22:305.
    PubMed     Abstract available

  174. HAN B, Zhen F, Zheng XS, Hu J, et al
    Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.
    BMC Cancer. 2022;22:297.
    PubMed     Abstract available

  175. SADAQA D, Farraj A, Naseef H, Alsaid H, et al
    Risk of developing depression among breast cancer patients in Palestine.
    BMC Cancer. 2022;22:295.
    PubMed     Abstract available

  176. CHAN KS, Cheung SM, Senn N, Husain E, et al
    Peri-tumoural spatial distribution of lipid composition and tubule formation in breast cancer.
    BMC Cancer. 2022;22:285.
    PubMed     Abstract available

  177. BHARDWAJ A, Embury MD, Ju Z, Wang J, et al
    Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer.
    BMC Cancer. 2022;22:282.
    PubMed     Abstract available

  178. JUNG H, Lu M, Quan ML, Cheung WY, et al
    New method for determining breast cancer recurrence-free survival using routinely collected real-world health data.
    BMC Cancer. 2022;22:281.
    PubMed     Abstract available

  179. DUAN F, Zhong M, Ma Y, Song C, et al
    The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).
    BMC Cancer. 2022;22:271.
    PubMed     Abstract available

  180. WANG C, Zhou Y, Lin Y, Mao F, et al
    Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    BMC Cancer. 2022;22:269.
    PubMed     Abstract available

  181. YE F, Bian L, Wen J, Yu P, et al
    Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    BMC Cancer. 2022;22:261.
    PubMed     Abstract available

  182. YANG PJ, Hou MF, Ou-Yang F, Tsai EM, et al
    Association of early-onset breast cancer with body mass index, menarche, and menopause in Taiwan.
    BMC Cancer. 2022;22:259.
    PubMed     Abstract available

  183. YANG TO, Cairns BJ, Pirie K, Green J, et al
    Body size in early life and the risk of postmenopausal breast cancer.
    BMC Cancer. 2022;22:232.
    PubMed     Abstract available

  184. CHEN YB, Bao HS, Hu TT, He Z, et al
    Comparison of comfort and complications of Implantable Venous Access Port (IVAP) with ultrasound guided Internal Jugular Vein (IJV) and Axillary Vein/Subclavian Vein (AxV/SCV) puncture in breast cancer patients: a randomized controlled study.
    BMC Cancer. 2022;22:248.
    PubMed     Abstract available

  185. HORIMOTO Y, Ishizuka Y, Ueki Y, Higuchi T, et al
    Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.
    BMC Cancer. 2022;22:242.
    PubMed     Abstract available

  186. LOMAN BR, Russart KLG, Grant CV, Lynch AJ, et al
    Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation.
    BMC Cancer. 2022;22:245.
    PubMed     Abstract available

  187. TANG R, Deng JP, Zhang L, Zhang WW, et al
    Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    BMC Cancer. 2022;22:234.
    PubMed     Abstract available

  188. ZHANG X, Mu X, Huang O, Wang Z, et al
    ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.
    BMC Cancer. 2022;22:226.
    PubMed     Abstract available

    February 2022
  189. PARK SY, Lim JW
    Cognitive behavioral therapy for reducing fear of cancer recurrence (FCR) among breast cancer survivors: a systematic review of the literature.
    BMC Cancer. 2022;22:217.
    PubMed     Abstract available

  190. ELBIAD O, Laraqui A, El Boukhrissi F, Mounjid C, et al
    Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    BMC Cancer. 2022;22:208.
    PubMed     Abstract available

  191. MARTEI YM, Dauda B, Vanderpuye V
    Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
    BMC Cancer. 2022;22:203.
    PubMed     Abstract available

  192. SARKER R, Islam MS, Moonajilin MS, Rahman M, et al
    Effectiveness of educational intervention on breast cancer knowledge and breast self-examination among female university students in Bangladesh: a pre-post quasi-experimental study.
    BMC Cancer. 2022;22:199.
    PubMed     Abstract available

  193. JUNG JG, Ahn SH, Lee S, Kim EK, et al
    No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
    BMC Cancer. 2022;22:189.
    PubMed     Abstract available

  194. CLOUD AS, Vargheese AM, Gunewardena S, Shimak RM, et al
    Loss of REST in breast cancer promotes tumor progression through estrogen sensitization, MMP24 and CEMIP overexpression.
    BMC Cancer. 2022;22:180.
    PubMed     Abstract available

  195. AMBROSIO MR, Magli E, Caliendo G, Sparaco R, et al
    Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells.
    BMC Cancer. 2022;22:171.
    PubMed     Abstract available

  196. GOTO W, Kashiwagi S, Kamei Y, Watanabe C, et al
    Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.
    BMC Cancer. 2022;22:167.
    PubMed     Abstract available

  197. VITALE SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, et al
    The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
    BMC Cancer. 2022;22:165.
    PubMed     Abstract available

  198. BRAHIMETAJ R, Willekens I, Massart A, Forsyth R, et al
    Improved automated early detection of breast cancer based on high resolution 3D micro-CT microcalcification images.
    BMC Cancer. 2022;22:162.
    PubMed     Abstract available

  199. LIAO Q, Deng D, Xie Q, Gong X, et al
    Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study.
    BMC Cancer. 2022;22:152.
    PubMed     Abstract available

  200. ANDREWS C, Childers TC, Wiseman KD, Lawhon V, et al
    Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.
    BMC Cancer. 2022;22:141.
    PubMed     Abstract available

  201. BU X, Jin C, Fan R, Cheng ASK, et al
    Unmet needs of 1210 Chinese breast cancer survivors and associated factors: a multicentre cross-sectional study.
    BMC Cancer. 2022;22:135.
    PubMed     Abstract available

  202. HEINIG M, Heinze F, Schwarz S, Haug U, et al
    Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery-an analysis of German claims data.
    BMC Cancer. 2022;22:130.
    PubMed     Abstract available

    January 2022
  203. GRAY LA, Hernandez Alava M, Wailoo AJ
    Correction to: Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    BMC Cancer. 2022;22:112.

  204. VAN EIJK M, Vermunt MAC, van Werkhoven E, Wilthagen EA, et al
    The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    BMC Cancer. 2022;22:104.
    PubMed     Abstract available

  205. ZHONG YM, Tong F, Shen J
    Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:102.
    PubMed     Abstract available

  206. GANESAMOORTHY D, Robertson AJ, Chen W, Hall MB, et al
    Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
    BMC Cancer. 2022;22:85.
    PubMed     Abstract available

  207. RAINEY L, van der Waal D, Donnelly LS, Southworth J, et al
    Women's health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations.
    BMC Cancer. 2022;22:69.
    PubMed     Abstract available

  208. SALAS M, Mordin M, Castro C, Islam Z, et al
    Health-related quality of life in women with breast cancer: a review of measures.
    BMC Cancer. 2022;22:66.
    PubMed     Abstract available

  209. TAKAMIZAWA S, Shimoi T, Satomi-Tsushita N, Yazaki S, et al
    Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
    BMC Cancer. 2022;22:64.
    PubMed     Abstract available

  210. ZHOU K, Ning F, Wang W, Li X, et al
    The mediator role of resilience between psychological predictors and health-related quality of life in breast cancer survivors: a cross-sectional study.
    BMC Cancer. 2022;22:57.
    PubMed     Abstract available

  211. EKSTROM K, Crescitelli R, Petursson HI, Johansson J, et al
    Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer.
    BMC Cancer. 2022;22:50.
    PubMed     Abstract available

  212. RAUTENBERG T, Hodgkinson B, Zerwes U, Downes M, et al
    Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer.
    BMC Cancer. 2022;22:52.
    PubMed     Abstract available

  213. VACHENC S, Gobbo J, Moujarrebe SE, Desmoulins I, et al
    OncoSNIPE(R) Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
    BMC Cancer. 2022;22:41.
    PubMed     Abstract available

  214. WANG S, Jiang H, Zheng C, Gu M, et al
    Secretion of BMP-2 by tumor-associated macrophages (TAM) promotes microcalcifications in breast cancer.
    BMC Cancer. 2022;22:34.
    PubMed     Abstract available

  215. OZAKI Y, Aoyama Y, Masuda J, Inagaki L, et al
    Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
    BMC Cancer. 2022;22:36.
    PubMed     Abstract available

  216. CHITAPANARUX I, Onchan W, Wongmaneerung P, Somwangprasert A, et al
    Integration of breast cancer care in a middle-income country: learning from Suandok Breast Cancer Network (SBCN).
    BMC Cancer. 2022;22:26.
    PubMed     Abstract available

  217. LI L, Ai L, Jia L, Zhang L, et al
    High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
    BMC Cancer. 2022;22:29.
    PubMed     Abstract available

  218. NAKAMOTO S, Watanabe J, Ohtani S, Morita S, et al
    Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
    BMC Cancer. 2022;22:31.
    PubMed     Abstract available

  219. BOUFERRAA Y, Haibe Y, Chedid A, Jabra E, et al
    The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
    BMC Cancer. 2022;22:27.
    PubMed     Abstract available

  220. LEE YJ, Kim Y, Choi BB, Kim JR, et al
    The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer.
    BMC Cancer. 2022;22:12.
    PubMed     Abstract available

  221. HAJJ A, Chamoun R, Salameh P, Khoury R, et al
    Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors.
    BMC Cancer. 2022;22:16.
    PubMed     Abstract available

  222. ESPOSITO MV, Fosso B, Nunziato M, Casaburi G, et al
    Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women.
    BMC Cancer. 2022;22:30.
    PubMed     Abstract available

  223. LAI Z, Brosnan M, Sokol ES, Xie M, et al
    Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    BMC Cancer. 2022;22:13.
    PubMed     Abstract available

    December 2021
  224. BARTMANN C, Fischer LM, Hubner T, Muller-Reiter M, et al
    The effects of the COVID-19 pandemic on psychological stress in breast cancer patients.
    BMC Cancer. 2021;21:1356.
    PubMed     Abstract available

  225. RADES D, Narvaez CA, Dziggel L, Janssen S, et al
    A prospective interventional study investigating sleep disorders prior to and during adjuvant radiotherapy for breast cancer.
    BMC Cancer. 2021;21:1349.
    PubMed     Abstract available

  226. OLSEN M, Fischer K, Bossuyt PM, Goetghebeur E, et al
    Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification.
    BMC Cancer. 2021;21:1351.
    PubMed     Abstract available

  227. KARSONO R, Haryono SJ, Karsono B, Harahap WA, et al
    ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.
    BMC Cancer. 2021;21:1348.
    PubMed     Abstract available

  228. RUFF GL, Murphy KE, Smith ZR, Vertino PM, et al
    Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation.
    BMC Cancer. 2021;21:1342.
    PubMed     Abstract available

  229. PARK HL, Chang J, Haridass V, Wang SS, et al
    Mammography screening and mortality by risk status in the California teachers study.
    BMC Cancer. 2021;21:1341.
    PubMed     Abstract available

  230. ZHANG MK, Wang B, Li SY, Liu G, et al
    TGF-beta1 and its signal molecules: are they correlated with the elasticity characteristics of breast lesions?
    BMC Cancer. 2021;21:1336.
    PubMed     Abstract available

  231. LIN S, Mo H, Li Y, Guan X, et al
    Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
    BMC Cancer. 2021;21:1330.
    PubMed     Abstract available

  232. XU D, Zhang Y, Jin F
    The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
    BMC Cancer. 2021;21:1321.
    PubMed     Abstract available

  233. LI F, Sun H, Li Y, Bai X, et al
    High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
    BMC Cancer. 2021;21:1305.
    PubMed     Abstract available

  234. ZHANG J, Jiang H, Zhang J, Bao G, et al
    Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
    BMC Cancer. 2021;21:1301.
    PubMed     Abstract available

  235. GIACOMELLI C, Jung J, Wachter A, Ibing S, et al
    Coordinated regulation of WNT/beta-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    BMC Cancer. 2021;21:1296.
    PubMed     Abstract available

  236. KEPESIDIS KV, Bozic-Iven M, Huber M, Abdel-Aziz N, et al
    Breast-cancer detection using blood-based infrared molecular fingerprints.
    BMC Cancer. 2021;21:1287.
    PubMed     Abstract available

  237. JIANG H, Meng L, Zhang H, Dai X, et al
    Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
    BMC Cancer. 2021;21:1284.
    PubMed     Abstract available

    November 2021
  238. MAZZONI AS, Brooke HL, Berntsen S, Nordin K, et al
    Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of the Phys-Can RCT.
    BMC Cancer. 2021;21:1272.
    PubMed     Abstract available

  239. MASUDA N, Tamura K, Yasojima H, Shimomura A, et al
    Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
    BMC Cancer. 2021;21:1269.
    PubMed     Abstract available

  240. XIN Y, Shen G, Zheng Y, Guan Y, et al
    Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1261.
    PubMed     Abstract available

  241. KLEIN I, Kalichman L, Chen N, Susmallian S, et al
    A comprehensive approach to risk factors for upper arm morbidities following breast cancer treatment: a prospective study.
    BMC Cancer. 2021;21:1251.
    PubMed     Abstract available

  242. SHI Y, Liu C
    Circular RNA hsa_circ_0043278 inhibits breast cancer progression via the miR-455-3p/EI24 signalling pathway.
    BMC Cancer. 2021;21:1249.
    PubMed     Abstract available

  243. GRAY LA, Hernandez Alava M, Wailoo AJ
    Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    BMC Cancer. 2021;21:1237.
    PubMed     Abstract available

  244. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
    Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study.
    BMC Cancer. 2021;21:1210.
    PubMed     Abstract available

  245. CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
    Correction to: Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
    BMC Cancer. 2021;21:1198.

  246. MIGEOTTE A, Dufour V, van Maanen A, Berliere M, et al
    Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
    BMC Cancer. 2021;21:1204.
    PubMed     Abstract available

  247. WANG Z, Hu S, Li X, Liu Z, et al
    MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
    BMC Cancer. 2021;21:1188.
    PubMed     Abstract available

  248. ZHAO XR, Fang H, Tang Y, Hu ZH, et al
    POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial.
    BMC Cancer. 2021;21:1185.
    PubMed     Abstract available

  249. VAN PARIJS H, Vinh-Hung V, Fontaine C, Storme G, et al
    Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.
    BMC Cancer. 2021;21:1177.
    PubMed     Abstract available

  250. WIJERATNE DT, Gunasekera S, Booth CM, Promod H, et al
    Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry.
    BMC Cancer. 2021;21:1175.
    PubMed     Abstract available

  251. XIE Y, Gong C, Zhang J, Wang L, et al
    Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
    BMC Cancer. 2021;21:1174.
    PubMed     Abstract available

    October 2021
  252. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
    Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
    BMC Cancer. 2021;21:1168.
    PubMed     Abstract available

  253. TANG W, Xu F, Zhao M, Zhang S, et al
    Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
    BMC Cancer. 2021;21:1160.
    PubMed     Abstract available

  254. CREEDEN JF, Nanavaty NS, Einloth KR, Gillman CE, et al
    Homologous recombination proficiency in ovarian and breast cancer patients.
    BMC Cancer. 2021;21:1154.
    PubMed     Abstract available

  255. SAJJADI E, Venetis K, Piciotti R, Gambini D, et al
    Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
    BMC Cancer. 2021;21:1152.
    PubMed     Abstract available

  256. KIM K, Kim IJ, Pak K, Kang T, et al
    Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative (18)F-FDG PET-CT in breast cancer: a retrospective cross-sectional study.
    BMC Cancer. 2021;21:1151.
    PubMed     Abstract available

  257. AL RABADI LS, Cook MM, Kaempf AJ, Saraceni MM, et al
    Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    BMC Cancer. 2021;21:1150.
    PubMed     Abstract available

  258. SHIMOI T, Hashimoto J, Sudo K, Shimomura A, et al
    Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
    BMC Cancer. 2021;21:1131.
    PubMed     Abstract available

  259. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.
    BMC Cancer. 2021;21:1129.
    PubMed     Abstract available

  260. BERTOZZI S, Londero AP, Viola L, Orsaria M, et al
    TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.
    BMC Cancer. 2021;21:1118.
    PubMed     Abstract available

  261. MERINO T, Pinto MP, Orellana MP, Martinez G, et al
    Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
    BMC Cancer. 2021;21:1114.
    PubMed     Abstract available

  262. AHSBERG K, Gardfjell A, Nimeus E, Ryden L, et al
    The PROCEM study protocol: Added value of preoperative contrast-enhanced mammography in staging of malignant breast lesions - a prospective randomized multicenter study.
    BMC Cancer. 2021;21:1115.
    PubMed     Abstract available

  263. HE Y, Tao Q, Zhou F, Si Y, et al
    The relationship between dairy products intake and breast cancer incidence: a meta-analysis of observational studies.
    BMC Cancer. 2021;21:1109.
    PubMed     Abstract available

  264. KIRKHAM AA, King K, Joy AA, Pelletier AB, et al
    Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise
    BMC Cancer. 2021;21:1093.
    PubMed     Abstract available

  265. TSUKAMOTO F, Arihiro K, Takahashi M, Ito KI, et al
    Multicenter retrospective study on the use of Curebest 95GC Breast for estrogen receptor-positive and node-negative early breast cancer.
    BMC Cancer. 2021;21:1077.
    PubMed     Abstract available

    September 2021
  266. LEE J, Jung JH, Kim WW, Kang B, et al
    Short-term serial assessment of electronic patient-reported outcome for depression and anxiety in breast Cancer.
    BMC Cancer. 2021;21:1065.
    PubMed     Abstract available

  267. LIN Y, Zhou X, Peng W, Wu J, et al
    Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
    BMC Cancer. 2021;21:1062.
    PubMed     Abstract available

  268. ABEBE E, Tollesa T, Assefa M, Tilahun Z, et al
    Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: an institution-based comparative cross-sectional study.
    BMC Cancer. 2021;21:1052.
    PubMed     Abstract available

  269. AKINYEMIJU T, Jones K, Gupta A, Oyekunle T, et al
    Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study.
    BMC Cancer. 2021;21:1051.
    PubMed     Abstract available

  270. RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
    Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
    BMC Cancer. 2021;21:1055.
    PubMed     Abstract available

  271. LIU J, Yin J, Liu Y, Xu Z, et al
    Characteristics of 1270 Chinese sibling pairs with cancer.
    BMC Cancer. 2021;21:1027.
    PubMed     Abstract available

  272. DIMITROVA D, Naghavi B, Richter R, Nasser S, et al
    Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
    BMC Cancer. 2021;21:1018.
    PubMed     Abstract available

  273. AMAYA C, Luo S, Baigorri J, Baucells R, et al
    Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
    BMC Cancer. 2021;21:981.
    PubMed     Abstract available

    August 2021
  274. TAVARES MC, Sampaio CD, Lima GE, Andrade VP, et al
    A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
    BMC Cancer. 2021;21:901.
    PubMed     Abstract available

    July 2021
  275. JIANG J, Chen J, Li W, Li Y, et al
    Inter-observer variations of the tumor bed delineation for patients after breast conserving surgery in preoperative magnetic resonance and computed tomography scan fusion.
    BMC Cancer. 2021;21:838.
    PubMed     Abstract available

  276. LAMBERT P, Pitz M, Singh H, Decker K, et al
    Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province : Using algorithms to determine breast and colorectal cancer recurrence.
    BMC Cancer. 2021;21:763.
    PubMed     Abstract available

    June 2021
  277. YOO TK, Park SH, Do Han K, Chae BJ, et al
    Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.
    BMC Cancer. 2021;21:735.
    PubMed     Abstract available

  278. GUO L, Xie G, Wang R, Yang L, et al
    Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
    BMC Cancer. 2021;21:717.
    PubMed     Abstract available

  279. BAKOS B, Kiss A, Arvai K, Szili B, et al
    Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden.
    BMC Cancer. 2021;21:706.
    PubMed     Abstract available

  280. YU J, Lin C, Huang J, Hong J, et al
    Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer.
    BMC Cancer. 2021;21:707.
    PubMed     Abstract available

  281. DHAKA B, Sabarinathan R
    Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
    BMC Cancer. 2021;21:669.
    PubMed     Abstract available

  282. KOTNIK U, Peterlin B, Lovrecic L
    Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
    BMC Cancer. 2021;21:665.
    PubMed     Abstract available

    May 2021
  283. ZHENG L, Zheng F, Xing Z, Zhang Y, et al
    Breast lesions excised via vacuum-assisted system: could we get any clues for B3 lesions before excision biopsy?
    BMC Cancer. 2021;21:633.
    PubMed     Abstract available

  284. KOTANI H, Terada M, Mori M, Horisawa N, et al
    Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
    BMC Cancer. 2021;21:548.
    PubMed     Abstract available

  285. YANG S, Bian J, George TJ, Daily K, et al
    The association between cognitive impairment and breast and colorectal cancer screening utilization.
    BMC Cancer. 2021;21:539.
    PubMed     Abstract available

  286. ZHOU X, Zheng Z, Li Y, Zhao W, et al
    The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study.
    BMC Cancer. 2021;21:536.
    PubMed     Abstract available

  287. YANG JR, Kuo WL, Yu CC, Chen SC, et al
    Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study.
    BMC Cancer. 2021;21:522.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.